<DOC>
	<DOCNO>NCT00567502</DOCNO>
	<brief_summary>This observational safety study conduct Europe compare patient take Xagrid patient take cytoreductive treatment . The plan enrol least 750 subject take Xagrid 3000 subject take cytoreductive therapy . The study collect follow data 5 year patient enrol focus collect data relate pre-defined event ( PDEs ) Suspected Serious Adverse Reactions ( SSARs ) .</brief_summary>
	<brief_title>Safety Pregnancy Outcomes Thrombocythemia Patients Exposed XAGRIDÂ® ( Anagrelide Hydrochloride ) Compared Other Treatments</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Anagrelide</mesh_term>
	<criteria>High risk ET patient Subjects give write informed consent . Subjects take cytoreductive therapy Contraindications list product use . Patient participate another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>